Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announces the appointment of Luciën van Os as Chief Operating Officer.
Luciën joins Xeltis with more than 20 years of experience in the life sciences sector, including a number of senior leadership roles at medical device companies. This includes driving international development activities for renal and cardiovascular products at both Medtronic and Gambro (acquired by Baxter International).
Prior to joining Xeltis, Luciën held CEO and COO positions at Magstim, Sphere Medical, and TMS International. Luciën has also served on the board of a number of medical technology startups including Ventinova. Luciën has a background in Computer Engineering and has held senior engineering positions at Ericsson and Philips.
“Luciën’s extensive experience in both executive and operational roles, as well as his deep understanding of both the renal and cardiovascular space, will be invaluable to Xeltis as we bring our transformative vascular implants to market,”
said Eliane Schutte, CEO of Xeltis.
Commenting on his appointment, Luciën van Os said:
“Xeltis’ groundbreaking vascular implant technology represents a significant improvement on standard of care available to hemodialysis and cardiovascular patients. I look forward to working with the management team closely as key trials progress over the coming months.”
Xeltis is a medtech company developing transformative implants that enable the natural creation of living and long-lasting vessels and valves. Xeltis’ devices seek to address the limitations of currently available options for the millions of people requiring hemodialysis access grafts or cardiovascular replacements every year.
The Company’s proprietary endogenous tissue restoration (ETR) platform utilizes an advanced polymer implant which regenerates the patient’s own tissue within and around it, before gradually being absorbed and leaving new, living and long-lasting vessels and valves in place. Xeltis’ devices currently under clinical development include aXessTM, implantable blood vessels for hemodialysis vascular access; XABGTM for coronary artery bypass graft (CABG) surgery; and Xplore 2TM for pediatric pulmonary heart valve replacement. Xeltis’ technology has high potential to be applied to other major vascular and cardiovascular diseases and represents a transformative technology for vascular and valve implants.
Xeltis is based in The Netherlands and the USA. Its investors include DaVita Venture Group, EQT Life Sciences, Kurma Partners, VI Partners, and Ysios Capital, as well as Grand Pharma Group and several public and private investors.
Eliane Schutte, CEO
Alexander Goemans, CFO
Consilium Strategic Communications
Amber Fennell / Chris Welsh
+44 (0) 20 3709 5700